Details

Autor(en) / Beteiligte

• Gilard, Martine
• Barragan, Paul
• Noryani, Arif A L
• Noor, Hussam A
• Majwal, Talib
• Hovasse, Thomas
• Castellant, Philippe
• Schneeberger, Michel
• Maillard, Luc
• Bressolette, Erwan
• Wojcik, Jaroslaw
• Delarche, Nicolas
• Blanchard, Didier
• Jouve, Bernard
• Ormezzano, Olivier
• Paganelli, Franck
• Levy, Gilles
• Sainsous, Joël
• Carrie, Didier
• Furber, Alain
• Berland, Jacques
• Darremont, Oliver
• Le Breton, Hervé
• Lyuycx-Bore, Anne
• Gommeaux, Antoine
• Cassat, Claude
• Kermarrec, Alain
• Cazaux, Pierre
• Druelles, Philippe
• Dauphin, Raphael
• Armengaud, Jean
• Dupouy, Patrick
• Champagnac, Didier
• Ohlmann, Patrick
• Endresen, Knut
• Benamer, Hakim
• Kiss, Robert Gabor
• Ungi, Imre
• Boschat, Jacques
• Morice, Marie-Claude

Titel

6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial

Ist Teil von

• Journal of the American College of Cardiology, 2015-03, Vol.65 (8), p.777-786

Ort / Verlag

United States

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute coronary syndrome (ACS). This study hypothesized that antiplatelet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive patients. A multicenter, randomized study assigned patients undergoing implantation of everolimus-eluting stents with confirmed nonresistance to aspirin to receive 6- or 24-month DAPT. The primary endpoint was a composite of death, myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding at 12 months post-stenting. A total of 2,031 patients were enrolled in 70 European and Middle Eastern centers. The trial was prematurely terminated due to recruitment problems, leaving 941 patients randomized to 24-month DAPT and 953 to 6-month DAPT. The 2 treatment groups had similar baseline and procedural characteristics. There was no significant difference in the primary endpoint (24-month: 1.5% vs. 6-month: 1.6%; p = 0.85). Noninferiority was demonstrated for 6- versus 24-month DAPT, with an absolute risk difference of 0.11% (95% confidence interval: -1.04% to 1.26%; p for noninferiority = 0.0002). There were no significant differences in stent thrombosis or bleeding complications. In the 792 (44%) high-risk patients with ACS, primary and secondary endpoints did not significantly differ (hazard ratio: 1.7 [95% confidence interval: 0.519 to 6.057; p = 0.361]). Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders. (Is There A LIfe for DES After Discontinuation of Clopidogrel [ITALICplus]; NCT01476020).